全文获取类型
收费全文 | 79112篇 |
免费 | 6005篇 |
国内免费 | 255篇 |
专业分类
耳鼻咽喉 | 907篇 |
儿科学 | 2046篇 |
妇产科学 | 1083篇 |
基础医学 | 10732篇 |
口腔科学 | 843篇 |
临床医学 | 8388篇 |
内科学 | 16970篇 |
皮肤病学 | 884篇 |
神经病学 | 7730篇 |
特种医学 | 3056篇 |
外科学 | 12805篇 |
综合类 | 885篇 |
一般理论 | 91篇 |
预防医学 | 5920篇 |
眼科学 | 1957篇 |
药学 | 5376篇 |
中国医学 | 94篇 |
肿瘤学 | 5605篇 |
出版年
2023年 | 607篇 |
2022年 | 842篇 |
2021年 | 2412篇 |
2020年 | 1360篇 |
2019年 | 2210篇 |
2018年 | 2528篇 |
2017年 | 1808篇 |
2016年 | 1897篇 |
2015年 | 2215篇 |
2014年 | 3209篇 |
2013年 | 4066篇 |
2012年 | 6515篇 |
2011年 | 6753篇 |
2010年 | 3692篇 |
2009年 | 3235篇 |
2008年 | 5393篇 |
2007年 | 5591篇 |
2006年 | 5184篇 |
2005年 | 5139篇 |
2004年 | 4636篇 |
2003年 | 4247篇 |
2002年 | 3850篇 |
2001年 | 594篇 |
2000年 | 395篇 |
1999年 | 566篇 |
1998年 | 787篇 |
1997年 | 588篇 |
1996年 | 477篇 |
1995年 | 425篇 |
1994年 | 399篇 |
1993年 | 395篇 |
1992年 | 250篇 |
1991年 | 197篇 |
1990年 | 178篇 |
1989年 | 162篇 |
1988年 | 156篇 |
1987年 | 129篇 |
1986年 | 132篇 |
1985年 | 144篇 |
1984年 | 181篇 |
1983年 | 150篇 |
1982年 | 236篇 |
1981年 | 232篇 |
1980年 | 164篇 |
1979年 | 94篇 |
1978年 | 114篇 |
1977年 | 99篇 |
1976年 | 69篇 |
1975年 | 59篇 |
1974年 | 49篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
4.
Triposkiadis Filippos Xanthopoulos Andrew Skoularigis John Starling Randall C. 《Heart failure reviews》2022,27(6):1991-2003
Heart Failure Reviews - The nitric oxide (NO)–guanylate cyclase (GC)–cyclic guanosine monophosphate (cGMP) pathway plays an important role in cardiovascular, pulmonary and renal... 相似文献
5.
6.
Xin Yi Wong Andrew Qi Jun Lim Qianyu Shen John Whay Kuang Chia Min Hoe Chew Wah Siew Tan 《Current medical research and opinion》2020,36(10):1677-1686
Abstract
Objective
Ras wild-type metastatic colorectal cancers (mCRC) may be treated with anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) agents. We aim to estimate patients’ preferences for mCRC treatment and relative importance of cost, efficacy improvement, avoidance of side effects and therapy convenience, and relative uptake between profiles that resemble Bevacizumab (anti-VEGF) and Cetuximab (anti-EGFR), two commonly prescribed mCRC targeted therapies. 相似文献7.
8.
Anuj Shrestha Zeeshan Jawa Kathryn L. Koch Amy B. Rankin Qun Xiang Anand Padmanabhan Matthew S. Karafin Joshua J. Field 《Journal of clinical apheresis》2015,30(6):353-358
Red cell exchange (RCE) is a common procedure in adults with sickle cell disease (SCD). Implantable dual lumen Vortex (DLV) ports can be used for RCE in patients with poor peripheral venous access. We performed a retrospective cohort study of RCE procedures performed in adults with SCD. The main objective of the study was to compare the inlet speed, duration of procedures and rate of complications performed through DLV ports to those performed through temporary central venous and peripheral catheters. Twenty‐nine adults with SCD underwent a total of 318 RCE procedures. Twenty adults had DLV ports placed and 218 procedures were performed using DLV ports. Mean length of follow‐up after DLV port placement was 397 ± 263 days. Six DLV ports were removed due to infection and 1 for malfunction after a mean of 171 ± 120 days. Compared to temporary central venous and peripheral catheters, DLV port procedures had a greater rate of procedural complications, a longer duration, and a lower inlet speed (all P < 0.01). When accounting for the maximum allowable inlet speed to avoid citrate toxicity, 40% of DLV port procedures were greater than 10% below maximum speed, compared to 7 and 14% of procedures performed through temporary central venous and peripheral catheters (P < 0.0001). In conclusion, DLV ports can be used for RCE in adults with SCD, albeit with more procedural complications and longer duration. The smaller internal diameter and longer catheter of DLV ports compared to temporary central venous catheters likely accounts for the differences noted. J. Clin. Apheresis 30:353–358, 2015. © 2015 Wiley Periodicals, Inc. 相似文献
9.
10.
William R. C. Knight Cara R. Baker Nyree Griffin Wahyu Wulaningsih Mark Kelly Andrew R. Davies James A. Gossage 《British journal of cancer》2021,124(10):1653
Background A high Mandard score implies a non-response to chemotherapy in oesophageal adenocarcinoma. However, some patients exhibit tumour volume reduction and a nodal response despite a high score. This study examines survival and recurrence patterns in these patients.Methods Clinicopathological factors were analysed using multivariable Cox regression assessing time to death and recurrence. Computed tomography-estimated tumour volume change was examined in a subgroup of consecutive patients.Results Five hundred and fifty-five patients were included. Median survival was 55 months (Mandard 1–3) and 21 months (Mandard 4 and 5). In the Mandard 4 and 5 group (332 patients), comparison between complete nodal responders and persistent nodal disease showed improved survival (90 vs 18 months), recurrence rates (locoregional 14.75 vs 28.74%, systemic 24.59 vs 48.42%) and circumferential resection margin positivity (22.95 vs 68.11%). Complete nodal response independently predicted improved survival (hazard ratio 0.34 (0.16–0.74). Post-chemotherapy tumour volume reduction was greater in patients with a complete nodal response (−16.3 vs −7.7 cm3, p = 0.033) with no significant difference between Mandard groups.Conclusion Patients with a complete nodal response to chemotherapy have significantly improved outcomes despite a poor Mandard score. High Mandard score does not correspond with a non-response to chemotherapy in all cases and patients with nodal downstaging may still benefit from adjuvant chemotherapy.Subject terms: Oesophageal cancer, Surgical oncology 相似文献